| Trial ID: | L6139 |
| Source ID: | NCT00130806
|
| Associated Drug: |
Mk0478 (Muraglitazar)
|
| Title: |
An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: MK0478 (muraglitazar)|DRUG: Comparator: placebo
|
| Outcome Measures: |
Primary: The difference in daily dose requirements of insulin after 24 weeks | Secondary: (a) HbA1C; (b) FPG; (c) Percent of patients with HbA1C <7.0%; (d) TG, HDL-C, non-HDL-C and apolipoprotein B; (e) Free Fatty Acids (FFA); (f) the incidence of hypoglycemic events at 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC | Collaborators: Bristol-Myers Squibb
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
600
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2005-09
|
| Completion Date: |
2005-11
|
| Results First Posted: |
|
| Last Update Posted: |
2016-09-07
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00130806
|
